Major Growth Influencing Factors:

The market for injectable drug delivery is expanding primarily as a result of growing government financing, rising chronic illness rates, and technical developments. The demand for pharmaceuticals and healthcare services is rising as the world's population ages. The need for injectable drugs to treat chronic illnesses and the complexity of their healthcare needs often lead to the growth of the injectable drug delivery market.

Projected Revenue Surge:

The size of global Injectable drug delivery market in terms of revenue was estimated to be worth $754.5 billion in 2024 and is poised to reach $1139.4 billion by 2029, growing at a CAGR of 8.6% from 2024 to 2029.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150

Emerging economies are seeing rapid urbanization, improved healthcare infrastructure, and more healthcare spending, resulting in greater access to injectable drugs. As a result, pharmaceutical companies are focusing on extending their presence in these markets to drive market growth.

Global Market Segmentation:

“By Therapeutic application, Infectious diseases holds the largest share in 2023.”

Injectable vaccines work to prevent infectious diseases by stimulating the production of antibodies by the immune system against target organisms. Vaccines are administered subcutaneously or intramuscularly to create immunity against a variety of illnesses, including COVID-19, polio, measles, influenza, and hepatitis. Drugs that are injectable are frequently used to treat HIV/AIDS and tuberculosis (TB), two chronic infectious diseases. Injectable therapies like rifampin, isoniazid, and streptomycin are often used with oral antibiotics in TB treatment to effectively target the germs and prevent medication resistance. Similarly, injectable antiretroviral drugs can be used to stop the spread of HIV/AIDS and lower viral replication in treatment regimens.

“By Usage Pattern Curative Care holds the largest share in 2023.”

The market is divided into three segments based on usage patterns: curative treatment, vaccination, and other usage patterns. Throughout the projection period, curative treatment will hold the biggest proportion. Injectable medications are often used to treat acute medical conditions that need for immediate attention in curative care settings, such as hospitals and emergency rooms. To treat infections, pain, and other acute symptoms, for example, injectable antibiotics, antivirals, and analgesics can be used.

This enables a quicker recovery and resolution of the illness. The exact administration of targeted medications based on individual patient characteristics, genetic profiles, and disease biomarkers is made possible via injectable pharmaceutical delivery. In order to specifically target cancer cells, change immunological responses, or fix genetic problems, targeted therapies—such as monoclonal antibodies, immunotherapies, and gene therapies—are injected. These interventions can cure patients or have effects that affect their condition.

End Users:

“Hospitals are the fastest-growing end users of the Injectable drug delivery market in 2023.”

Based on end users, the Injectable drug delivery market is segmented into Hospitals and Retail Pharmacy centres. Hospitals serve a wide range of medical disciplines, including surgery, cancer, cardiology, neurology, infectious diseases, and others, all of which may necessitate injectable drugs for diagnosis, treatment, or prevention. Injectable medications are utilised in a variety of medical fields to provide targeted therapies, perform diagnostic tests, and offer supportive care to patients. Hospitals perform a variety of medical procedures and interventions, including surgeries, diagnostic imaging, interventional radiology, and therapeutic interventions, which may necessitate the use of injectable drugs before, during, or following the treatment. Injectable medications are used extensively in anesthesia, sedation, pain management, contrast enhancement, and other procedures, which contributes to the overall demand for injectable drug delivery in hospital settings.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=150

“North America dominates the global Injectable drug delivery market in 2023.”

The Injectable drug delivery market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2023 North America accounted for the largest share during the forecast period due to the following reasons- North America has one of the world's highest healthcare costs, thanks to innovative medical technologies, expensive prescription drug prices, and a comprehensive healthcare insurance system. The readiness to invest in novel healthcare solutions, such as injectable drug delivery systems, helps to drive market growth and adoption in the region. North America is home to world-class clinical research institutes, university medical centres, and pharmaceutical research hubs that perform clinical trials, translational research, and technology development for injectable drug delivery. Collaborations among academia, industry, and government organizations promote innovation and the translation of scientific discoveries into clinical practice.

Key Players:

The prominent companies are Becton, Dickinson and Company (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Eli Lilly and Company (U.S.), Baxter International, Inc. (U.S.), Sandoz (Germany), Terumo (Japan), Schott AG (Germany), Gerresheimer (Germany), Ypsomed (Switzerland), Bespak (U.K.), and B. Braun Melsungen (Germany).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]